Roche signs $1.7bn deal with Blueprint around cancer drug pr...

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations. 

Blueprint pays the price of Ayvakit phase 3 miss as FDA reje...

FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.

Lilly keeps ahead of Blueprint with swift FDA review for sel...

Ipsen adds Blueprint's FOP rare disease drug to pipeline for...

Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a  licence to develop and market a drug for the rare disease fibrodysplasia ossifican